Lilly teams up with SanegeneBio in a US$1.2 billion RNAi deal to develop tissue-targeted metabolic therapies using ...

Some stocks are similar to the tortoise in Aesop's famous fable, "The Tortoise and the Hare." Others are like the hare. But ...

Q3 2025 Earnings Call November 10, 2025 8:30 AM ESTCompany ParticipantsKate Rausch - Head of Investor RelationsPaul Bolno ...

City Therapeutics, Inc., a biopharmaceutical company leading the future of RNA interference (RNAi)-based medicine, today ...

Company plans to initiate a Phase 1 study in early 2026 with initial human data expected late 2026 Company's first clinical-stage program headlines a diverse and novel pipeline poised to deliver ...

SanegeneBio is responsible for discovering and identifying optimised RNAi molecules for each programme through its LEAD ...

A total of 3 analyst ratings have been received for WAVE Life Sciences, with the consensus rating being Buy. The average ...

Benitec Biopharma ( ($BNTC) ) has provided an announcement. On November 5, 2025, Benitec Biopharma announced the pricing of a public offering of ...

The aggregate gross proceeds to Benitec from the underwritten public offering and the concurrent registered direct offering are expected to be approximately $100 million, prior to deducting ...

Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA- ...

A biotech stock with strong FDA approval odds this November may see limited upside amid a full valuation and a pending lawsuit.

On November 3, 2025, Privium Fund Management B.V. reported selling 138,263 shares of Arrowhead Pharmaceuticals ( ARWR 1.57%) ...